Literature DB >> 6796885

Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases.

A A Woodcock, E R Gross, A Gellert, S Shah, M Johnson, D M Geddes.   

Abstract

We measured breathlessness and exercise tolerance in 12 patients with chronic airways obstruction, moderate or severe breathlessness, and low or normal arterial carbon dioxide tension, after the patients received dihydrocodeine, alcohol, caffeine, or placebo (through double-blind administration). Forty-five minutes after ingestion, dihydrocodeine had reduced breathlessness by 20 per cent and increased exercise tolerance by 18 per cent, with a reduction in ventilation and oxygen consumption at submaximal work loads but with no change in spirometric volumes. Oxygen also reduced breathlessness and provided additional benefit to that achieved with dihydrocodeine (at three hours after ingestion) when the two were given together: the reduction of breathlessness was 18 per cent with dihydrocodeine; 22 per cent with oxygen; and 32 per cent with dihydrocodeine plus oxygen. Alcohol increased forced vital capacity by 9 per cent, and exercise tolerance by 7 per cent. Caffeine had no deleterious effect on breathlessness or exercise tolerance, despite increasing ventilation during rest and exercise. We conclude that opiates may be valuable for the treatment of breathlessness in selected patients; further evaluation is needed, particularly of the long-term benefits and safety.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796885     DOI: 10.1056/NEJM198112313052703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  35 in total

1.  Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease.

Authors:  R Leung; P Hill; J Burdon
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 2.  Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline.

Authors:  Darcy D Marciniuk; Donna Goodridge; Paul Hernandez; Graeme Rocker; Meyer Balter; Pat Bailey; Gord Ford; Jean Bourbeau; Denis E O'Donnell; Francois Maltais; Richard A Mularski; Andrew J Cave; Irvin Mayers; Vicki Kennedy; Thomas K Oliver; Candice Brown
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 3.  The management of dyspnea in cancer patients: a systematic review.

Authors:  Raymond Viola; Cathy Kiteley; Nancy S Lloyd; Jean A Mackay; Julie Wilson; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2008-01-24       Impact factor: 3.603

4.  BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.

Authors: 
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

Review 5.  A systematic review of the use of opioids in the management of dyspnoea.

Authors:  A-L Jennings; A N Davies; J P T Higgins; J S R Gibbs; K E Broadley
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

Review 6.  Breathlessness.

Authors:  A Cockcroft; A Guz
Journal:  Postgrad Med J       Date:  1987-08       Impact factor: 2.401

Review 7.  Caffeine and endurance performance.

Authors:  S K Powers; S Dodd
Journal:  Sports Med       Date:  1985 May-Jun       Impact factor: 11.136

8.  Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.

Authors:  I H Young; E Daviskas; V A Keena
Journal:  Thorax       Date:  1989-05       Impact factor: 9.139

Review 9.  Palliative management of refractory dyspnea in COPD.

Authors:  Hope E Uronis; David C Currow; Amy P Abernethy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Hyperinflation and its management in COPD.

Authors:  Luis Puente-Maestu; William W Stringer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.